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Open access under CThe remarkable success of therapeutic applications of immunoglobulin G (IgG) in form of monoclonal
antibodies and pooled immunoglobulin G preparations has directed attention to this class of glycopro-
teins. It is commonly appreciated that oligosaccharides attached to the Fc-region play a critical role in
the biological activity of IgGs. Thus, glycosylation has been a focus of interest for many scientists and
the biopharmaceutical industry and expression hosts have been engineered in order to optimize antibody
products. In this review we focus on efforts towards a targeted manipulation of IgG-Fc N-glycans using
non-mammalian expression hosts, i.e. yeast, insect cells and plants. Current achievements in generating
human-like N-glycan structures will be presented and recent data on the molecular mechanisms that
might explain how these potent drugs mediate in vivo activities will be discussed.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
Glycosylation, the attachment of sugar moieties to a given pro-
tein backbone, is a largely conserved posttranslational modiﬁca-
tion in multicellular organisms. In humans, more than 50% of
proteins are estimated to be glycosylated [1]. Especially serum gly-
coproteins form a heterogeneously glycosylated mixture of an
otherwise homogeneous protein backbone (microheterogeneity).
The glycosylation proﬁle of these proteins is determined by the
amino acid sequence, by the conformation at the glycosylation site,
by the presence of glycan modifying enzymes and by the availabil-
ity of suitable activated sugar substrates. In contrast to other bio-
synthetic functions like DNA-, RNA- or protein synthesis,
glycosylation is not under direct transcriptional control and not
based on a template. Given the high number of possible glycans at-
tached to proteins, manifold functions can be attributed to the car-
bohydrate moiety: folding, stability, conformation, solubility,
quality control, half-life, oligomerization or functionality. Thus,
(proper) glycosylation is vital for most eukaryotes and proteins
with speciﬁc N-glycosylation patterns are needed in research as
well as for medical applications.
Immunoglobulins (Igs)1 are prominent examples for serum gly-
coproteins. Depending on the immunological response 5 different
Ig-isotypes exist in humans with unique structural and functional
properties (further details see [2, this issue]). Some of the isoformsos), herta.steinkellner@boku.
unoglobulin G; mAbs, mono-
cc receptor; XT, b1,2-xylosyl-
virus inhibition assays.
C BY-NC-ND license. carry up to 7 glycosylation sites (e.g. IgE) and oligosaccharide struc-
tures can account for 10–20% of the molecular weight [3, personal
communication Friedrich Altmann, BOKU Wien, Austria]. Sequence
alignment between different immunoglobulin classes and subclasses
indicates the presence of a homologous N-glycosylation site in all of
them, except IgA [4]. This conservation indicates an important role of
the N-glycan attached at this speciﬁc site for structural integrity and/
or function of Ig-Fc domains [2, this issue, 5].
Immunoglobulins show a considerable microheterogeneity
regarding their glycans. Taking the large human glycome into ac-
count, this microheterogeneity may comprise several hundred gly-
coforms and is mainly owed to the presence or absence of sialic
acid, galactose, core-fucose and bisecting N-acetylglucosamine
(GlcNAc) [5–7]. IgG, the simplest immunoglobulin isoform, con-
tains one single N-glycosylation site in the constant domains
(Asn297), representing the conserved site present in most Ig-clas-
ses. For IgGs, Jefferis [2, this issue, 6] estimated a theoretical num-
ber of 128 neutral IgG-glycoforms not including charged residues
like sialic acid. The oligosaccharide composition of IgGs, the pre-
dominant antibody class present in serum, is relatively well char-
acterized [e.g. [8,9]]. Studies of the Fc-N-glycans of serum IgG
from healthy individuals revealed several unique characteristics,
like a very low degree of sialylation [recently reviewed by Kobata
[10]]. This comes as a surprise, since most other serum glycopro-
teins are highly sialylated. However, as discussed by Jefferis [2]
(this issue) the glycosylation pattern of serum IgG can vary dra-
matically. Differences in IgG glycosylation were noticed e.g. during
different diseases, pregnancy and ageing, indicating that some of
these variably present glycan residues might play a role in ﬁne-
tuning the antibody activity and thus contribute to an optimal
immune answer [11]. This microheterogeneity clearly complicates
the investigation of the speciﬁc functionalities conferred by a
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mixture of only a few different ones might already be challenging
[12], not even taking into account the high microheterogeneity of
human serum immunoglobulins. Still, the availability of proteins
carrying one single oligosaccharide structure can be of high impor-
tance for therapeutics, where different glycoforms show different
functionality, as in the case of IgGs. There, the absence or presence
of core fucose within the Fc-glycan has been linked to the afﬁnity
for the Fc receptor and thus the strength of effector functions
[13,14]. The reason for this impact has recently been shown to
lie in the interaction between the N-glycans of IgG and receptor
[15]. This interaction can only take place in an optimal way when
the IgG is devoid of core fucose.
Apart from producing more effective drugs, researchers are also
dependent on pure glycoforms in their efforts to link speciﬁc func-
tions to speciﬁc glycosylation patterns. Thus, if puriﬁcation from a
heterogeneously glycosylated mix is impossible, production of sin-
gle glycoforms is of utmost importance. Currently, most therapeu-
tic monoclonal antibodies (mAbs) are produced in mammalian cell
lines (CHO, NS0, SP2/0, . . .). In contrast to the 30–40 glycoforms
normally detected in human IgG, mammalian cell-derived mAbs
carry usually only 5–9 different N-glycan structures and some hu-
man-like oligosaccharides are insufﬁciently produced, if at all (e.g.
bisected, di-galactosylated or sialylated structures) [9]. Moreover,
it is currently virtually impossible to obtain single glycoform-mAbs
from mammalian cell lines. These observations reveal shortcom-
ings of mammalian expression platforms, limited availability of
naturally present serum glycoforms and too high glycan-heteroge-
neity. Success to overcome these limitations is relatively modest
(intensively discussed by Jefferis [2, this issue, 5]) as the large,
endogenously present glycome complicates a targeted manipula-
tion of the glycosylation proﬁle of mammalian cells.
As outlined above and by Jefferis [2, this issue], the availability
of single glycoforms is needed in fundamental research and medi-
cine. This review focuses on strategies for the in vivo synthesis of
custom-made IgG glycoforms with low glycan-heterogeneity in
non-mammalian expression hosts and highlights recent ﬁndings
in this area. A special focus is given to plant glycoengineering.Glycosylation pathways
Protein biosynthesis is a relatively conserved process, thus
allowing the expression of heterologous proteins in a wide variety
of hosts like bacteria, yeast, insect and mammalian cells and plants.
N-glycosylation on the other hand can vary strongly between spe-
cies, between different cell lines of the same species or even be-
tween different culture conditions. Notwithstanding these
obstacles, the demand for advanced glycoprotein expression plat-
forms has fueled different glycoengineering approaches.
In common with mammalian cells, N-glycosylation of newly
synthesized proteins in insect, yeast and plant cells is initiated in
the endoplasmic reticulum (ER) by the oligosaccharyltransferase
complex, which transfers the oligosaccharide precursor
Glc3Man9GlcNAc2 onto the growing polypeptide chain, more spe-
ciﬁcally, onto a suitable asparagine residue within the N-glycosyl-
ation consensus sequence (Asn-Xaa-Ser/Thr). This precursor is
subsequently trimmed to Man8GlcNAc2 (Man8) and the protein is
then transferred to the Golgi, where further processing occurs
(Fig. 1; oligosaccharide abbreviations see: www.proglycan.com).
At the point of Man8 the N-glycosylation pathway between yeasts
and other eukaryotes diverges. In yeasts, further mannose residues
are attached resulting in high-mannosidic structures while in other
eukaryotes Man8 ﬁrst undergoes further trimming and can then be
extended with GlcNAc, galactose, sialic acid, fucose and/or xylose
to give rise to hybrid, complex or paucimannosidic N-glycans(Fig. 1). Despite these species-speciﬁc differences in N-glycosyla-
tion, engineering of the respective pathways in non-mammalian
expression hosts delivered remarkable results.Fc glycoengineering in yeast
As an intensively used production platform for recombinant
proteins and because of the ease to manipulate the genome by
homologous recombination, yeast (particularly Saccharomyces cer-
visiae, Pichia pastoris) was one of the ﬁrst and most successful tar-
gets of glycoengineering. Like other eukaryotes, yeasts synthesize
ER located Man8 oligosaccharides. Upon translocation to the Golgi,
several mannosyltransferases elongate Man8, resulting in large
hypermannsoylated glycans that can contain over 100 mannose
residues. Such glycoforms are not present in humans, they are thus
potentially immunogenic, might alter protein functions and lead to
a reduced half-life of therapeutic products. In order to direct the
yeast glycosylation pathway towards the synthesis of human-like
structures two major issues had to be envisaged: (i) elimination
of yeast-speciﬁc glycosylation reactions and (ii) introduction of
the missing compounds of the human pathway. Indeed, knock
out of yeast mannosyltransferase genes prevented hypermannosy-
lation and provided appropriate acceptor substrates for further
processing steps [16]. Finally, overexpression of a series of glycan
modifying mammalian enzymes allowed the reconstruction of
the human glycosylation pathway, including terminal sialylation
[17]. To date, this work stands as one of the most remarkable
achievements in glycan engineering.
In the course of the humanization of the yeast N-glycosylation
pathway seven different, to a large extent pure glycoforms of the
cancer-speciﬁc mAb rituximab were produced and functional
activities were compared to commercial Rituxan [14]. Two of the
structures were of complex type, without and with galactose
(GnGn and AA, respectively), two carried oligo-mannosidic struc-
tures, which represent human intermediates (Man8, Man5). Fur-
ther forms comprised the tri-mannose core structure Man3 (as
typical for insect cells, see below), a hybrid form (Man5Gn) and
wild-type yeast hypermannosylated mAb. Notably, all yeast oligo-
saccharides lacked core fucosylation while about 90% of Rituxan N-
glycans contained this glycan moiety. Fcc receptor (FccR) binding
studies using different Fcc receptors revealed that different ritux-
imab glycoforms show a clearly different binding afﬁnity for FccRs.
This variation was particularly pronounced for the low afﬁnity
receptor variant FccRIIIa-F158, where binding afﬁnity could be
raised over 100 fold for GnGn and AA carrying mAbs as compared
to commercial Rituxan. In addition, improved activities of glycoen-
gineered rituximab that carried GnGn and Man5Gn structures were
conﬁrmed in B-cell depletion assays, which measure antibody-
dependent cell killing [14]. This was the ﬁrst report demonstrating
the in vivo generation of different mAb glycoforms at great unifor-
mity. The study clearly demonstrates the altered performance of
different glycoforms, verifying observations made with mamma-
lian cell-derived mAbs [18,19]. The possible applicability to indus-
try was shown by a recent study demonstrating commercially
viable production levels for mAbs produced in glycoengineered
yeast [20]. However, pharmacokinetic and clinical studies of such
glycoengineered mAbs are pending.Fc glycoengineering in insect cells
The baculovirus-insect cell expression system is a versatile and
efﬁcient eukaryotic expression system particularly well suited for
posttranslationally modiﬁed proteins [21]. Different glycosylation
reactions than in mammalian cells can, however, pose a problem
for the therapeutic use of mammalian glycoproteins produced in
Fig. 1. Schematic presentation of selected components of the N-glycosylation pathways in humans, yeast, insect cells and plants. The common ER-resident oligosaccharide
precursor Man8 acts as starting point for further modiﬁcations along the Golgi apparatus. Och1: a1,6-mannosyltransferase; MnTs: mannosyltransferases; Mns: mannosidase;
GnT: N-acetylglucosaminyltransferase; GalT: a1,4-galactosyltransferase; ST: a2,6-sialyltransferase; HEXO: hexosaminidase (N-acetylglucosaminidase); XT: b 1,2-xylosyl-
transferase; FT: core fucosyltransferase; Fucose can be transferred in a1,3-linkage (plant typical) and a1,6-linkage (mammalian typical). Interestingly, both forms are
synthesized in insect cells. Oligosaccharide abbreviations according to www.proglycan.com.
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are very similar, further steps differ [22,23]. Formation of complex
N-glycans is initiated – as in mammalian cells – by the addition of
an N-acetylglucosaminylresidue to the intermediate Man5 struc-
ture and subsequent cleavage of mannose residues. However, in
contrast to mammalian cells, further processing comprises trim-
ming of GlcNAc residues by hexosamminidases (HEXO) resulting
in the generation of insect-typical paucimannosidic N-glycans. In
addition, fucose can be attached to the innermost GlcNAc residue
in a1,6- and in a1,3-position (Fig. 1), the latter being absent in
mammals. The non-mammalian structures present on insect-cell
derived glycoproteins may reduce the in vivo bioactivity of thera-
peutics and might even lead to immunogenic or allergenic reac-
tions [21]. Thus, substantial work has been done to modify N-
glycan processing pathways in insect cells in order to generate
mammalian-like N-glycans. This ﬁnally led to the production of
glycoproteins with mammalian-type glycosylation, includingprotein sialylation [24,25]. However, only a few reports investigate
the potential biological impact of insect-speciﬁc glycosylation. For
IgGs, insect-type Fc-glycosylation does neither signiﬁcantly alter
antigen-binding nor effector functions like CDC when compared
to CHO-produced counterparts [26]. On the other hand, mAbs with
paucimannosidic N-glycans have been shown to mediate ADCC at
signiﬁcantly lower (50- to 100-fold lower) effector-to-target cell
ratios [27]. Further investigations are needed to fully judge the per-
formance of insect cell-derived (glycoengineered) mAbs. Recent re-
sults demonstrating the efﬁcient generation of different mAb
glycoforms in newly developed insect cells will allow to ﬁll that
gap in the near future [28].
Fc glycoengineering in plants
Plants have a longstanding history for the expression of thera-
peutically relevant recombinant proteins [29]. Due to the largely
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highly complex molecules, like IgGs and IgAs, can be efﬁciently
produced [30]. Drastic increases in production speed and yield of
recombinant proteins have placed plants in a favourable position
[31,32]. Particularly the fast production of grams of puriﬁed mAbs
within a few days after delivery of the appropriate DNA construct
to plants [33] provides unique advantages in cases where produc-
tion speed is of utmost importance, as recently reported for the
generation of individualized idiotype IgGs [34].
In contrast to other expression platforms, plants provide
the advantage that they synthesize mammalian-type complex
N-glycans. En block transfer of the Glc3Man9GlcNAc2 precursor
onto the growing protein and subsequent trimming in ER and
cis/medial-Golgi compartments are virtually identical in mammals
and plants up to the synthesis of GnGn structures (Fig. 1). Beyond
that point the glycosylation pathways diverge. In mammals, GnGn
structures undergo intensive elongation/modiﬁcation processes,
while plants normally do not further elongate the outer arms of
the glycans. On the other hand, plant cells add xylose in b1,2-posi-
tion to the innermost mannose residue and fucose in a1,3-position
to the innermost GlcNAc residue of the GnGn core oligosaccharide
(Fig. 1). These residues are not present in mammalian cells, and are
consequently, due to reasons discussed above, undesirable. Due to
the largely conserved N-glycosylation pathway between mammals
and plants the latter provide good prerequisites for glycoengineering.
Importantly, mAbs produced in plants exhibit a N-glycosylation
proﬁle with a single dominant oligosaccharide structure, GnGnXF3.
Pioneering work towards the humanization of the plant glycosyla-
tion pathway was carried out by Palacpac et al. [35] and Bakker
et al. [36,37]. The two groups overexpressed the human b1,4-
glacatosyltransferase (GalT) in tobacco plants and cells in order
to elongate the plant-typical GnGnXF3 by b1,4-galactose. This
approach resulted in galactosylated structures and it drastically
reduced the degree of xylosylation and fucosylation. Although
these proof of concept studies demonstrated the ability of plants
to synthesize human-type structures by simply overexpressing a
mammalian glycosylation enzyme, the overall mAb glycosylation
pattern was far from optimal, exhibiting unexpected glycoforms,
like incompletely processed and hybrid structures [35–38].
Another major breakthrough towards the humanization of the
plant N-glycosylation pathway was the generation of mutants
lacking plant-speciﬁc b1,2-xylose and core a1,3-fucose. This was
achieved by the elimination of the responsible endogenous en-
zymes, b1,2-xylosyltransferase (XT) and core a1,3-fucosyltransfer-
ase (FT3, Fig. 2). Using knock-down and knock-out approaches for
the respective genes, mutant plant lines of Arabidopsis thaliana,
Lemna minor, Nicotiana benthamiana and the moss Physcomitrella
patenswere generated (DXT/FT plants) and used for the productionFig. 2. Fc-Glycoengineering in plants. Overview of mAb glycoforms generated in glyco
recombinant protein production. IgG N-glycans generated (1) in wild-type plants: GnGn
DXTFT + GalT: AA [45,46]; (5) in DXT/FT along with six mammalian genes of the mamm
a1,6-fucosyltransferase, GalT: b1,4-galactosyltransferase, ST: a2,6-sialyltransferase,
www.proglycan.com.of different mAbs [39–44]. Notably, the Fc-N-glycosylation proﬁles
of these mAbs contained GnGn as a single dominant structure, with
no detectable b1,2-xylose or a1,3-fucose residues remaining. Bio-
logical activity assays of these glycoengineered mAbs revealed
unaffected antigen binding and CDC activity, however, signiﬁcantly
enhanced ADCC potency as compared to mAbs produced in wild-
tpye plants and CHO cells was observed [39,42,45]. These results
are in accordance with those obtained using fucose free mAbs pro-
duced in other expression platforms. Surprisingly, despite the
availability of different expression platforms that permit the gen-
eration of such glycoengineered mAbs (yeast, mammalian cells,
plants) a direct comparison of their functional activities has not
been reported. Thus, at the moment, their performance cannot be
fully judged yet.
Elimination of b1,2-xylose and core a1,3-fucose not only dem-
onstrated the ability of plants to synthesize human-type structures
without showing any obvious phenotype but also permitted the
generation of GnGn, the substrate for further modiﬁcations in
mammals, such as galactosylation, sialylation, branching, introduc-
tion of a bisecting GlcNAc or fucosylation (Figs. 1 and 2).
Targeting of the GalT to a late Golgi compartment signiﬁcantly
improved b1,4-galactosylation in DXT/FT plants. mAbs produced
in such glycoengineered plants exhibited a single dominant Fc-N-
glycan structure, namely digalactosylated AA [45,46], an oligosac-
charide generated in insufﬁcient amounts by most mammalian
production lines, however dominant in serum IgG [9]. Interestingly,
mAbs against HIV produced in such glycoengineered plants exhib-
ited improved anti-viral activity as determined by cell-based virus
neutralization assays [45]. Several conﬂicting reports have been
published dealing with the role of terminal galactose residues in
modulating IgG activity [11]. As discussed by Jefferis [2, this issue]
the degree of antibody galactosylation in the serum can vary during
pregnancy and aging and is in certain cases associated with
diseases. This observation indicates an active role of this N-glycan
residue in modulating IgG activity in vivo. Glycoengineered plants
as described above provide a suitable platform for the production
of digalactosylated antibodies to further investigate the importance
of this abundant IgG glycoform.
A minor, yet frequently found glycan moiety on human serum
IgG is bisecting GlcNAc, i.e. GlcNAc bound in b1,4-position to the
innermost mannose residue [9]. To date no clear contribution to
mAb or IgG activities have been assigned to this oligosaccharide
residue. One publication [47] reported enhanced ADCC activity of
mAb CAMPATH-1H when containing increased amounts of bi-
sected structures. For glycoengineered Rituxan and Herceptin con-
taining an elevated portion of bisecting GlcNAc an enhanced ADCC
activity has been reported as compared to mAbs produced in
non-modiﬁed cells [48]. However, these results are in conﬂict withengineered Nicotiana benthamiana, a tobacco related plant species widely used for
XF3 [59]; (2) in DXT/FT3 plants: GnGn [59]; (3) in DXT/FT + FT6: GnGnF6 [55]; (4) in
alian sialic acid pathway: NaNa [57]; (6) in wild-type + GnTIII: GnGnXF3bi [46]. FT6:
GnTIII: N-acetylglucosaminyltransferase III. Glycan abbreviations according to
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ferent mAbs upon increasing the bisected fraction [49]. The change
in ADCC seems rather owed to an decrease in a1,6-fucosylation
caused by blocking of the fucosyltransferase through attachment
of the bisecting GlcNAc residue [50]. The synthesis of bisected
structures in CHO cells – achieved by the overexpression of
the corresponding enzyme N-acetylglucosaminyltransferase III
(GnTIII) – led to the generation of additional, atypical hybrid struc-
tures with signiﬁcantly reduced core-fucose content [18,51]. Thus,
investigating the effect of bisected residues on the function of
mAbs remains difﬁcult using exclusively mammalian cells.
Initially, overexpression of GnTIII in plants resulted in a similar
observation as in mammalian cells, mAbs carried bisected oligo-
saccharides, however accompanied by atypical, incompletely pro-
cessed structures [52]. Interestingly, such hybrid structures can
be avoided by targeting the enzyme to a later stage of the plant gly-
cosylation pathway [46]. Using targeting sequences that direct the
enzyme to the trans-Golgi compartment resulted in the generation
of mAbs carrying around 40% fully processed, bisected structures.
As addition of bisecting GlcNAc inhibits further oligosaccharide
processing in mammalian cells [50], elongation/trimming of N-gly-
cans obviously needs to be completed prior to GnTIII activity in or-
der to obtain complex, bisected oligosaccharides. Surprisingly, in
the DXT/FT mutant, which lacks plant-speciﬁc core modiﬁcations,
smaller amounts of bisecting glycoforms were synthesized as com-
pared to wild-type plants [46]. An observation, which cannot be
entirely explained. Nevertheless, the generation of mAbs carrying
large fractions of bisected GnGnXF3bi structures now paves the
way to further investigate the contribution of this oligosaccharide
moiety to the modulation of mAb or IgG activities.
In recent yearsmanipulation of corea1,6-fucosylation came into
the focus of interest, since major contributions to mAb activities
have been assigned to that N-glycan residue (detailed description
see [2, this issue]). Several studies have been published attempting
the modulation of this N-glycan residue in mammalian cells. How-
ever, to date it is not possible to generate mAbs in mammalian cells
with identical N-glycosylation proﬁles differing only in the pres-
ence/absence of core fucose. Usually the removal of fucose is accom-
panied by additional changes in the overall N-glycosylation pattern
[18,53,54]. Thus, it cannot be excluded that these differences may
contribute at least to some extend to altered mAb activities.Fig. 3. Reconstruction of the human sialylation pathway in plants using the endogenou
acetylglucosamine 2-epimerase/N-acetylmannosamine-kinase (GNE), N-acetylneuramin
CMP-Neu5Ac transporter (CST), b1,4-galactosyltransfease (GT) and a2,6-sialyltransferase
correct subcellular deposition of genes/proteins for (i) biosynthesis (GNE, NANS), (ii) activ
(ST) [57]. Glycan abbreviations according to www.proglycan.com.However, usingglycomodiﬁedDXT/FTplants itwaspossible to com-
pletely restore mammalian-type core a1,6-fucosylation by over-
expressing the responsible mammalian enzyme, core a1,6-
fucosyltransferase (Fig. 2). This allowed the generationofmAbswith
andwithout fucosewhilemaintaining an otherwise identical N-gly-
cosylation pattern [46,55]. In the course of these experiments the
impact of Fc-glycosylation on the antiviral activity of the broadly
neutralizing HIV-1 mAb 2G12 was investigated. Different plant-de-
rived2G12batches exhibitedglycosylationproﬁles containinga sin-
gle dominant N-glycan structure, amongst them 2G12 carrying
GnGnXF3, GnGnF6, GnGn and digalactosylated AA structures. CHO-
derived 2G12 on the other hand carried a mixture of six N-glycans.
The plant-derived 2G12 glycoforms differed only in one or two gly-
can residues, thus allowing precise investigations of the impact of
single glycan moieties on Ab activity [55]. All 2G12 glycoforms
exhibited similar binding to FccRI, FccRIIa, and FccRIIb. In contrast,
binding of 2G12 to FccRIIIa was markedly affected by core fucose,
irrespective of its plant-speciﬁc a1,3- or mammalian-type a1,6-
linkage. Consistent with this ﬁnding, 2G12 glycoforms lacking core
fucose mediated higher antiviral activity against various lentivirus-
es (incl. HIV-1) as measured by antibody dependent cell-mediated
virus inhibition assays (ADCVI), an equivalent to ADCC induction
by anti-cancer mAbs. In addition the results indicate that further
elongation of GnGn by terminal b1,4-galactose (AA structures) does
not signiﬁcantly enhance 2G12 ADCVI. So far this is the only study
that investigated in vitro and in vivo antiviral activity of glycoengi-
neeredmAbs, pointing to the importance of optimalN-glycosylation
for immunotherapeutic reagents [55].
The ﬁnal and most complex step of human N-glycosylation is
terminal sialylation. There is long-standing evidence that IgG mol-
ecules can have an anti-inﬂammatory activity in autoimmune dis-
eases and recent studies indicate that this activity is associated
with the presence of sialic acid (for further description see [2, this
issue, 56]). However, detailed studies that back this important phe-
nomenon are hampered by the difﬁculties in obtaining highly
sialylated IgG, a glycoform present only in low quantities in serum
and inefﬁciently synthesized in mammalian cells. Moreover,
CHO cells naturally attach sialic acid in a2,3-position, whereas
a2,6-linkage is the preferred type on serum IgG.
Sialylation is particularly difﬁcult to accomplish in plants
because plants lack some essential prerequisites along thesly present metabolite UDP-GlcNAc. Enzymes involved in the process are: UDP-N-
ic acid phosphate-synthase (NANS), CMP-sialic acid (Neu5Ac) synthetase (CMAS),
(ST). In planta protein sialylation was achieved by the coordinated expression and
ation (CMAS), (iii) transport (CST), and (iv) transfer of Neu5Ac to terminal galactose
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ta sialylation of mAbs was recently reported [57]. Castilho et al.
had introduced enzymes of the mammalian pathway into plants,
allowing the biosynthesis of sialic acid, its activation, its transport
into the Golgi, and ﬁnally its transfer onto terminal galactose
(Fig. 3). mAbs coexpressed with the genes from the human sialyla-
tion pathway carried up to 80% sialylated structures [57]. A
remarkable number considering the required coordinated overex-
pression of six mammalian enzymes which act at various stages
and in different subcellular compartments of the biosynthetic
pathway. Notably, in planta sialylation did not have a negative im-
pact on mAb expression, which is remarkable in the light of the
complexity of both processes.
At the time this review is written experiments are underway
that investigate possible contributions of Fc sialylation to IgG
activities.
Conclusion
To fully understand the different immunoglobulin activities,
more than protein–protein interactions alone have to be consid-
ered. The oligosaccharide moiety of IgG-Fcs has shown to wield
inﬂuence on their various functions, indicating that this glycan is
more than a simple building block required solely for correct three
dimensional conformation and stability. The absence or presence
of this glycan or even of single sugar residues can strongly inﬂu-
ence the mode of action and the different glycoforms present in
serum during different physiological stages, e.g. disease, aging or
pregnancy, indicate a certain level of active control over the
N-glycosylation machinery. Only now we are starting to uncover
the factors that govern differential N-glycosylation and how
N-glycans affect different IgG functions. In this respect, access to
pure glycoforms is a crucial prerequisite enabling more detailed
structure–function studies that will have an impact on medicine
as well. For example, IgGs lacking core fucose have been shown
to possess a drastically improved in vivo activity and thus have
raised interest as next-generation mAbs with improved efﬁcacy
[54,58]. The effects of other naturally occurring Fc-glycoforms
however remain largely unknown. The generation of different sin-
gle glycoforms will further increase our knowledge of structure–
function relations of IgG glycosylation and allow the production
of mAbs with even higher clinical potency. The here described
glycoengineered expression platforms will signiﬁcantly contribute
to advances in this ﬁeld.
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